Clinical Trial Update: A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating disitamab vedotin in combination with bicalutamide for HER2/AR-positive extramammary Paget's disease of the scrotum; currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extramammary Paget Disease
• Scrotal Paget Disease

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• bicalutamide (bicalutamide)

Snippet

Sponsor: Fudan University | Conditions: Extramammary Paget Disease, Scrotum Disease | Phase 2 | Status: RECRUITING